title: Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.
authors.forename: G Kesava
authors.initials: GK
authors.lastname: Reddy
authors.forename: Manisha
authors.initials: M
authors.lastname: Guputa
authors.forename: Preeta
authors.initials: P
authors.lastname: Tyagi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D066246:ErbB Receptors; D006801:Humans; D000077146:Irinotecan; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D066246:ErbB Receptors; D000068818:Cetuximab; D002166:Camptothecin